COMMANDS Post Hoc Analysis: Outcomes With First-Line Luspatercept in Lower-Risk MDS With Early Disease Characteristics

Amer Zeidan, MBBS, unpacks results from a post hoc analysis of the phase 3 COMMANDS trial assessing luspatercept (Reblozyl) in patients with lower-risk myelodysplastic syndromes (MDS) and early disease characteristics. He highlights outcomes across relevant subgroups and discusses implications for patient selection. Zeidan explains how these findings may further refine first-line treatment strategies.